에 대한 최신 뉴스 FinVolution Gr (NYSE:FINV) 주식

FinVolution Gr

FinVolution Group is a provider of online consumer finance in China. It offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers Tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company provides investors with an opportunity to invest in emerging asset class-consumer loans through a variety of investment options. It generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC and its revenues are derived from within the PRC.

Opinion

Trading Ideas

BABA

FINV

TCOM

많은 국가가 2025년까지 지출을 줄이려고 노력하고 있지만, 주목할 만한 국가 중 한 곳은 바로 중국이다. 중국 정부는 침체된 경제를 부양하기 위해 일련의 경기 부양책을 약속해 왔으며, 지난주 은행 부문에 550억 달러(4,000억 위안) 이상을 투입하겠다고 발표하면서 이러한 금전적 약속 중 하나가 이행되었다.알리바바 JD닷컴 핀볼루션 트립닷컴

중국의 대규모 부양책 속 매수할 만한 주식 4종목

FinVolution Group American Depositary Shares

FinVolution Group

Barrington Research analyst Gary Prestopino maintains Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) with a Outperform and maintains $110 price target.

News

Price Target

Analyst Ratings

DAVE

Barrington Research Maintains Outperform on Dave, Maintains $110 Price Target

Shares of Target Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) are trading lower in <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket on Tuesday</a> after the fourth-quarter FY24 earnings.
The company reported a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44103957/target-corporation-reports-fourth-quarter-and-full-year-2024-earnings" rel="noreferrer noopener">fourth-quarter sales decline </a>of 3.1% year-on-year to $30.91 billion, beating the analyst consensus estimate of $30.84 billion.
Comparable sales increased 1.5% in the fourth quarter, reflecting strong traffic and digital performance. Digital comparable sales grew 8.7%.
Adjusted EPS of $2.41 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus</a> estimate of $2.26.
Gross margin for the quarter contracted by 40 basis points to 26.2%, reflecting higher digital fulfillment and supply chain costs and higher promotional and clearance markdown rates.
Operating&nbsp;income margin rate of 4.7% was 110 basis points lower than last year, and the&nbsp;operating income for the quarter plunged 21.3% to $1.47 billion.
The&nbsp;company held $4.7 billion in cash and equivalents&nbsp;as of February 1.&nbsp;Operating cash flow for twelve months totaled $7.4 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/03/44081963/ford-february-us-sales-slide-8-9-ev-sales-jump-15-details" rel="noreferrer noopener">Ford February US Sales Slide 8.9%, EV Sales Jump 15%: Details</a>
Inventory as of February was $12.74 billion, compared to $11.8 billion last year. The company paid dividends of $513 million in the fourth quarter, compared with $508 million last year.
As of the end of the fourth quarter, TGT had approximately&nbsp;$8.7 billion&nbsp;of remaining capacity under the repurchase program approved by the Board of Directors in&nbsp;August 2021.
&#8220;Our team grew traffic and delivered better-than-expected sales and profitability in our biggest quarter of the year,&#8221;&nbsp;said chair and chief executive officer Brian Cornell.
&#8220;Results were led by strong performance in Beauty, Apparel, Entertainment, Sporting Goods and Toys. As we look ahead, our continued investments in digital capabilities, stores and supply chain—combined with a focus on newness, value, speed and reliability—will further differentiate our one-of-a-kind physical and digital shopping experience.&#8221;
Outlook: Target expects FY25 adjusted EPS of $8.80 – $9.80 versus an estimate of $9.31. It sees comparable sales to be flat. The company sees FY25 sales growth <a href="https://www.benzinga.com/calendars/guidance">to be around 1%.</a>
Due to continued consumer uncertainty, a slight drop in February net sales, tariff instability, and the anticipated timing of certain expenses throughout the fiscal year, the company expects to face significant year-over-year profit challenges in the first quarter compared to the rest of the year.
&#8220;During February, we saw record performance around Valentines Day. However, our topline performance for the month was soft, as uncharacteristically cold weather across the U.S. affected apparel sales, and declining consumer confidence impacted our discretionary assortment overall,&#8221; said&nbsp;Jim Lee, chief financial officer.
Price Action: TGT shares traded lower by 1.88% at $118.49 in premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44074819/servicenow-unveils-ai-agents-for-telecoms-in-collaboration-with-nvidia" target="_blank" rel="noreferrer noopener">ServiceNow Unveils AI Agents For Telecoms In Collaboration With Nvidia</a></li>
</ul>
Photo via Shutterstock.

Earnings

Equities

Large Cap

Guidance

Movers

General

Target CEO Cautions Tariffs Will Pressure FY25 Profit, Consumer Uncertainty To Hit Feb Sales

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) with a Buy and maintains $16 price target.

Reiteration

CALC

HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

Biotech

HOTH

Hoth Therapeutics Announces Preclinical Findings On Potential Of Glial Cell Line-Derived Neurotrophic Factor; Says Findings Include Protection Against High-Fat Diet-Induced Obesity, Enhanced Fat Burning and Energy Expenditure, Adipogenesis, Improved Insulin Sensitivity and Glucose Regulation And Reduced Fatty Liver Disease

Mizuho analyst Gregg Moskowitz maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Outperform and lowers the price target from $80 to $72.

GTLB

Mizuho Maintains Outperform on GitLab, Lowers Price Target to $72

Telsey Advisory Group analyst Cristina Fernandez maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Outperform and maintains $67 price target.

ONON

Telsey Advisory Group Maintains Outperform on On Holding, Maintains $67 Price Target

Barclays analyst Ramsey El-Assal downgrades AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) from Overweight to Equal-Weight and lowers the price target from $13 to $8.

Downgrades

AVDX

Barclays Downgrades AvidXchange Holdings to Equal-Weight, Lowers Price Target to $8

On Tuesday, BioHarvest Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) published ‘in vitro' test results for its new olive cell compound, which can reduce fat accumulation in human liver cells.
BioHarvest demonstrated that its novel olive cell compound mitigated fat accumulation in human liver cells, both in a liver steatosis model and in experimental liver fibrosis models.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/12/42431837/exclusive-bioharvest-collaborate-with-tate-lyle-to-develop-proprietary-plant-based-molecules" rel="noreferrer noopener">EXCLUSIVE: BioHarvest Collaborates With Tate &amp; Lyle To Develop Proprietary Plant-Based Molecules</a>
The company attributes the reduction of fat accumulation in liver cells to the high levels of Verbascoside (a plant-derived polyphenol with known anti-inflammatory properties that has been researched for various effects on the liver) in BioHarvest's Olive cell compound.
Based on these results and additional studies to be conducted in 2025, the company expects to begin selling the Olive Cell product in 2026 as a nutraceutical product while continuing to explore the potential of partnering with a pharmaceutical company to provide the olive cell composition via a different regulatory path as part of its contract development and production organization (CDMO) model.
The Olive product will join VINIA as part of the company's portfolio. VINIA, a grape cell product that is high in Piceid Resveratrol, has been clinically shown to significantly dilate arteries, resulting in increased blood flow.
The company recently announced that VINIA had surpassed $50 million in sales, with over 50,000 active subscribers.
BioHarvest plans to support future growth by expanding its production capacity by 4x and building a new 100-ton-per-year production facility, which is expected to be <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/43780365/bioharvest-announces-sales-of-flagship-product-vinia-now-exceed-50-million-usd" rel="noreferrer noopener">operational in late 2026</a>.
Price Action: BHST stock closed at $5.03 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44103926/grocery-giant-albertsons-names-susan-morris-as-new-ceo" target="_blank" rel="noreferrer noopener">Grocery Giant Albertsons Names Susan Morris As New CEO</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

BHST

EXCLUSIVE: Botanical Synthesis Tech-Focused BioHarvest's First Synthetic Olive Cells Shows Reduced Fat Accumulation in Liver Cells

<a href="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions" title="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions">https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions</a>

Johnson & Johnson MedTech Says 'Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform In U.S. To Transform Treatment Of Difficult-To-Cross Calcified Lesions'

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

MARA

MARA Holdings February Bitcoin Product 706 Down From 750 MoM

EXCLUSIVE: BioHarvest Tells Benzinga 'In Vitro Testing of First Lab-Grown Plant-Based Molecules Proves Reduced Fat Accumulation in Liver Cells'

EXCLUSIVE: BioHarvest Tells Benzinga Co. Shows First Synthetic Olive Cells A Capable New Weapon In Fight Against Liver Disease

Parent Company Discusses Strategy to Evolve into a Broader Holding Company with a Focus on Emerging Technologies
NEW YORK, March 4, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>)&nbsp;(the "Company") today announced that its wholly-owned subsidiary, Dominari Securities LLC ("Dominari"),&nbsp;has received approval for its Continuing Membership Application ("CMA") from the Financial Industry Regulatory Authority ("FINRA"). The Company also provided additional commentary regarding its plans to develop into a broader holding company with a focus on emerging technologies.

DOMH

Dominari Securities Receives FINRA Approval For Its CMA To Expand Operations

WIIM

BeiGene shares are trading higher after the company announced FDA approval of Tevimbra/chemotherapy combination.

On March 3, 2025, iCoreConnect, Inc. (the "Company") entered into warrant cancellation agreements with the holders of warrant to purchase an aggregate of 142,690 shares of common stock. The canceled warrants included anti-dilution provisions that could have led to an increase in the number of warrants and a reduction in the exercise price if new shares were issued by the Company at a lower price.
 &nbsp;

ICCT

iCoreConnect On Mar. 3 Entered Into Warrant Cancellation Agreements With The Holders Of Warrant To Purchase An Aggregate Of 142,690 Shares Of Common Stock

&nbsp;
Tiziana Life Sciences, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) (&quot;Tiziana&quot; or the &quot;Company&quot;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement in the company&#39;s commitment to advance a new treatment approach for Amyotrophic Lateral Sclerosis (ALS) which is supported by the ALS Association.
This IND filing follows the prestigious award of a grant as part of the Hoffman ALS Clinical Trial Awards Program from the ALS Association. Tiziana&#39;s intranasal foralumab development programs are now focused on 3 neurodegenerative diseases. ALS, Multiple Sclerosis, and Alzheimer&#39;s disease. This grant provides a framework for industry-academia collaboration where new discoveries are translated to clinical studies through innovative research and development.
ALS, also known as Lou Gehrig&#39;s disease is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its clinical course can be rapid with marked disability even at an early stage. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. The disease is always fatal, usually within five years of diagnosis. Despite its devastating impact, treatment options remain limited, highlighting the critical importance of advancing research efforts like those undertaken by Tiziana Life Sciences.

TLSA

Tiziana Life Sciences Announces Investigational New Drug Application Submission For Phase 2 Trial Of Intranasal Foralumab In ALS

- STAR-1 topline results expected by the end of March 2025 -
- Over 30 million acne patients seek treatment in the U.S. each year -
- XYNGARI&#x2122; Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S.&nbsp; and Latin America -

DRMA

Dermata Announced Last Patient Completed Last Visit In XYNGARI Phase 3 STAR-1 Clinical Trial For Acne

New controlled study published in&nbsp;Journal of Nutrition and Dietary Supplements highlights statistically significant reductions in ethanol levels following acute alcohol intake
SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or the "Company"), a wellness and dietary supplement company, today announces the peer-reviewed publication of its groundbreaking randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy of Safety Shot&#xAE; in mitigating the negative effects of alcohol consumption. The study, published in the Journal of Nutrition and Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62), demonstrates that Safety Shot&#xAE; statistically significantly reduces blood alcohol concentration (BAC), breath alcohol concentration (BrAC), and hangover symptoms compared to placebo (p &lt; 0.05), and at a remarkably faster rate than the body's natural processes. For the complete article, visit the website at: <a href="https://www.globenewswire.com/Tracker?data=WMrB5FCJ7spqdDFaiGgaOalIPHMLw7p7IOTyw0oAzKQ3WxqFYU0LFhPAP0b-gLXh5BNsAX0_KrPK6x9IyWGObFFPAF2q9v4zTdH-7dHHILiW1TDVIt0rcNZlwME-V15r">https://doi.org/10.2147/NDS.S507571</a>

SHOT

Safety Shot Announces First Peer-Reviewed Publication Of Human Clinical Trial Confirming Rapid Alcohol Reduction And Hangover Prevention Published In The Journal Of Nutrition And Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62)

Mizuho analyst Vijay Rakesh maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Outperform and raises the price target from $58 to $68.

MCHP

Mizuho Maintains Outperform on Microchip Technology, Raises Price Target to $68

MASS

908 Devices shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS and revenue estimates.

Fintech

Press Releases

FinVolution Publishes Sixth Annual ESG Report

FinVolution Group to Report Second Quarter 2024 Financial Results on Tuesday, August 20, 2024

FinVolution Group Reports Second Quarter 2024 Unaudited Financial Results

FinVolution Subsidiary AdaKami Enters into Strategic Funding Agreement with PT Super Bank, Indonesia

FinVolution Group to Report Third Quarter 2024 Financial Results on Monday, November 18, 2024

FinVolution Group Reports Third Quarter 2024 Unaudited Financial Results

FinVolution Showcases Innovative Credit Solutions and Highlights a Collaborative Fintech Future at AFF 2025

FinVolution's SVP Ming Gu speaks at Asian Financial Forum, highlighting opportunities in CreditTech for Southeast Asia's underserved

Contracts

FinVolution's Philippine Subsidiary Partners with Security Bank to Drive Financial Inclusion

FinVolution Group to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Monday, March 17, 2025

Ally Financial

American Express

Bread Financial Holdings, Inc. Common Stock

Bread Finl Hldgs

Credit Acceptance Corporation - Common Stock

Credit Acceptance

Capital One Financial Corporation Common Stock

Capital One Finl

Dave

Discover Financial servs

Encore Capital Gr

Enova International

FirstCash Hldgs

Joint Stock Company Kaspi.kz - American Depository Shares

Kaspi.kz

LendingClub

Lufax Holding Ltd American Depositary Shares, each representing two (2) Ordinary Shares

Lufax Holding

LexinFintech Holdings Ltd. - American Depositary Shares

LexinFintech Holdings

MoneyLion

Navient

Nelnet

OneMain Holdings

PRA Group

PROG Holdings

Qifu Technology, Inc - American Depositary Shares

Qifu Technology

SoFi Techs

Synchrony Financial

Upstart Hldgs

Daiwa Capital

Citigroup

CICC

많은 국가가 2025년까지 지출을 줄이려고 노력하고 있지만, 주목할 만한 국가 중 한 곳은 바로 중국이다. 중국 정부는 침체된 경제를 부양하기 위해 일련의 경기 부양책을 약속해 왔으며, 지난주 은행 부문에 550억 달러(4,000억 위안) 이상을 투입하겠다고 발표하면서 이러한 금전적 약속 중 하나가 이행되었다.
관세 여부와 관계없이 오늘 소개하는 4가지 주식은 급등할 수 있다.
이번 자금 투입은 성장이 절실한 중국의 수요를 촉진하기 위한 광범위한 경기 부양책의 일환이다. 중국의 인플레이션은 2023년 초부터 거의 제로에 가까웠고, 생산자 물가는 실제로 2년 연속 하락했다.
미국의 소비자들은 2021년, 2022년, 2023년에 평균 4%가 넘는 CPI를 기록한 후 연간 0.2%의 인플레이션 수치를 환영할 수 있지만, 중국 경제는 어려움을 겪고 있으며 상하이종합지수(SSE)는 2022년 초부터 계속 정체되고 있다.
하지만 정부가 경기 부양책을 내놓으면서 투자자들이 다시 활기를 띠기 시작했고, 몇몇 대형 중국 기업이 직접적인 수혜자가 될 수 있다.
오늘은 중국 정부의 경기 부양책의 수혜를 받을 수 있는 미국 상장 중국 기업 4곳을 살펴보고자 한다. 이 기업들은 대부분 대형주이지만 다양한 산업과 부문에 걸쳐 있다. 또한 이들 주식 중 일부는 2월 말 트럼프 행정부의 새로운 관세 위협 이후 주가가 하락했는데, 3월이 시작되면서 현명한 투자자에게는 매수 기회가 될 수 있다.
<h3 class="wp-block-heading">알리바바 그룹 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)</h3>
알리바바는 마침내 제대로 된 이유로 헤드라인을 장식하고 있다. 최근 실적 보고서는 애널리스트들로부터 수많은 투자의견 상향을 이끌어냈다. 중국 이커머스 대기업 알리바바는 2월 20일 보고서에서 매출 및 순이익 모두에서 예상치를 초과 발표하여 주가 상승을 이끌었고, 연초 대비(YTD) 50% 이상의 상승률을 기록했다. 특히 핵심 마켓플레이스 매출(CMR)과 AI가 접목된 알리클라우드(AliCloud) 부문과 같은 주요 영역에서 견고한 성장세를 보였다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-806846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154849/ali-1024x415.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154849/ali-1024x415.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154849/ali-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154849/ali-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154849/ali.png 1309w" alt="" width="1024" height="415" /></figure>
이러한 수치와 12월 중국 소매판매가 전년 대비 3.7% 증가했다는 점을 감안하면 알리바바 주가는 추가 상승의 발판을 마련한 것으로 보인다. 금요일에는 새로운 관세 위협으로 인해 주가가 하락했지만, 애널리스트들이 등급과 목표주가를 상향 조정하면서 강세 기조가 강화되었다.
2월 20일 실적 보고서가 나온 후 번스타인과 모건스탠리는 즉시 보유에서 매수 의견으로 상향 조정했고, JP모건, BofA 증권, 바클레이즈, 벤치마크의 애널리스트들 역시 모두 목표주가를 올렸다. 새로운 목표주가 중 가장 낮은 가격(150달러)은 2월 28일 종가 대비 12.6%의 상승 여력이 있음을 의미한다.
<h3 class="wp-block-heading">트립닷컴 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)</h3>
중국의 엄격한 코로나19 제한 조치로 여행 수요가 위축되었지만, 트립닷컴은 코로나19에 대해 알기 훨씬 전부터 어려움을 겪고 있었다. 2017년 7월 주가는 사상 최고치를 기록한 후 이후 5년 동안 꾸준히 하락했다. 2022년 10월에는 2014년 수준으로 급락했고, 2022회계연도에는 상당한 손실을 기록할 것으로 예상되었다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-806847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154856/tri-1024x415.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154856/tri-1024x415.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154856/tri-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154856/tri-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154856/tri.png 1309w" alt="" width="1024" height="415" /></figure>
그러나 트립닷컴 주가는 2022년 마지막 몇 달 동안 턴어라운드하기 시작했다. 2023년의 고르지 못한 주가 흐름 이후, 2024년에 주가가 급등하여 7년 만에 사상 최고치를 기록했다. 트립닷컴 주가는 2025년을 시작하며 하락세로 돌아섰고, 불과 몇 주 만에 77달러에서 56달러로 떨어졌다.
하지만 이러한 하락은 투자자들에게는 기회가 될 수 있다. 트립닷컴은 부채가 적고 수익의 16배에 불과한 주가로 거래되고 있다. 최근 2024년 4분기 실적에서 매출과 순이익 모두 예상치를 초과했다. 벤치마크와 JP모건은 각각 80달러와 75달러의 목표주가를 제시하고 매수 의견을 반복했다. 75달러는 현재 수준에서 거의 28% 상승 여력이 있는 가격이다.
기술적 관점에서 볼 때 상대강도지수(RSI)가 주요 임계치인 30까지 계속 하락함에 따라 곧 과매도 신호를 유발할 수 있다.
<h3 class="wp-block-heading">핀볼루션 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>)</h3>
핀볼루션 그룹은 시가총액이 21억 4,000만 달러에 불과해 이 목록에서 가장 작은 주식이다. 하지만 다른 종목들과 마찬가지로 오랜 고군분투 끝에 2024년에 부활의 조짐을 보였다. 핀볼루션은 온라인 마켓플레이스를 통해 소비자와 대출자를 연결하는 데 중점을 둔 핀테크 기업이다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-806848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154903/inv-1024x415.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154903/inv-1024x415.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154903/inv-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154903/inv-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154903/inv.png 1309w" alt="" width="1024" height="415" /></figure>
핀볼루션 주가는 2021년 밈 주식 열풍이 불었을 때 단 3개월 만에 2달러 미만에서 8달러 이상으로 급등하며 큰 화제를 모았다. 하지만 대부분의 밈 주식과 마찬가지로 FINV도 2022년 3월에는 열풍 이전 수준으로 돌아갔다. 오늘날 주가는 소매업의 광풍이 아닌 진정한 성장 덕분에 주당 8달러에 가까운 가격으로 다시 거래되고 있다.
핀볼루션은 지난 12개월 동안 주당순이익이 12% 이상 성장했지만, 여전히 순방향 주가수익비율 5.65, 주가순자산비율 0.58로 수익의 7배에 불과한 수준에서 거래되고 있다. 핀볼루션은 2025년에 EPS가 13% 이상 성장할 것으로 예상하고 있으며, 주가는 이미 2025년에 21% 이상 상승했다. 시가총액이 작기 때문에 애널리스트의 커버리지는 적지만 펀더멘털과 기술적 신호 모두 앞으로 더 많은 잠재적 이익을 가리킨다.
<h3 class="wp-block-heading">JD닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)</h3>
알리바바닷컴이 타사 구매자와 판매자를 위한 비즈니스 마켓플레이스라면 JD닷컴은 중국판 아마존에 가깝다. JD닷컴은 세계에서 가장 광범위한 이커머스 운영과 고품질 제품 및 고객 서비스로 명성을 얻고 있다. 600억 달러의 시가총액은 알리바바의 3,150억 달러에 비하면 미미한 수준이지만, JD닷컴은 인상적인 수익 성장에도 불구하고 여전히 저평가되어 있다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-806849" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154911/jD-1024x415.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154911/jD-1024x415.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154911/jD-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154911/jD-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154911/jD.png 1309w" alt="" width="1024" height="415" /></figure>
JD닷컴 주가는 2021년 초에 정점을 찍은 후 급격한 하락을 경험했다. 2021년 1월에 100달러를 돌파한 주가는 2024년 1분기 초에 22달러 아래로 급락했다. 80% 하락은 위험 감수성이 높은 투자자도 겁을 먹기에 충분하지만, 작년에 회사가 안정화되면서 주가는 반등하기 시작했다. JD닷컴은 최근 4분기 동안 1,563억 3,000만 달러의 매출을 올렸으며, 이는 이전 4분기보다 3% 증가한 수치다.
JD닷컴은 3월 6일에 2024년 4분기 실적을 발표할 예정이며, 애널리스트들은 코로나19 사태 이후 최고치인 450억 달러의 매출을 예상하고 있다. 바클레이즈는 2월 28일 보고서를 앞두고 목표주가를 50달러에서 55달러로 상향 조정했는데, 이는 현재 시장 가격 대비 24% 높은 수준이다.
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

FinVolution Gr

뉴스

에 대한 최신 뉴스 FinVolution Gr (NYSE:FINV) 주식

화요일, 3월 04, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌